Social Distancing

June 4, 2020

Antiviral Therapeutics and Vaccines

  • A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
    Authors conducted a randomized, double-blind, placebo-controlled trial across the United States and parts of Canada testing hydroxychloroquine as postexposure prophylaxis. Authors enrolled adults who had household or occupational exposure to someone with confirmed Covid-19 at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure). Within 4 days after exposure, participants were randomly assigned to receive either placebo or hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 additional days). The primary outcome was the incidence of either laboratory-confirmed Covid-19 or illness compatible with Covid-19 within 14 days. After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure.

Diagnostics

  • Predicting infectious SARS-CoV-2 from diagnostic samples
    RT-PCR has become the primary method to diagnose viral diseases, including SARS-CoV-2. RT-PCR detects RNA, not infectious virus, thus its ability to determine duration of infectivity of patients is limited. Infectivity is a critical determinant in informing public health guidelines/interventions. Authors goal was to determine the relationship between E gene SARS-CoV-2 RT-PCR cycle threshold (Ct) values from respiratory samples, symptom onset to test (STT) and infectivity in cell culture. SARS-CoV-2 Vero cell infectivity was only observed for RT-PCR Ct < 24 and STT < 8 days. Infectivity of patients with Ct >24 and duration of symptoms >8 days may be low.

Epidemiology

Situation Dashboards

World_Health_Organization_logo_logotype

World Health Organization (WHO)

Novel Coronavirus (COVID-19) Situation from World Health Organization (WHO)
university-logo-small-horizontal-blue-no-clear-space-51c7fb4524

Johns Hopkins University (JHU)

Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at JHU
1point3acres

COVID-19 in US and Canada

1Point3Acres Real-Time Coronavirus (COVID-19) Updates in US and Canada with Credible Sources
image

Genomic Epidemiology COVID-19

Genomic Epidemiology of (COVID-19) Maintained by the Nextstrain team, enabled by data from GISAID.

Sources for COVID-19 Information

World_Health_Organization_logo_logotype

World Health Organization (WHO)

1280px-US_CDC_logo.svg

Centers for Disease Control, US

ProMED-Logo

International Society for Infectious Diseases

twiv-logo

This Week in Virology (TWIV)

Receive updates about Parasites without Borders initiatives, developments, and learn more about parasites by subscribing to our periodic newsletter.


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Parasites Without Borders

Un recurso educativo integral sobre todos los aspectos de las enfermedades parasitarias y su impacto en la humanidad en todo el mundo.

¡Done a los Parásitos Sin Fronteras hoy!

Ayude a llevar la información médica y biológica más reciente sobre enfermedades causadas por parásitos eucariotas a todos los médicos y estudiantes de medicina en los Estados Unidos.

Scroll to Top